DETROIT ? Allied Minds, a pre-seed investment corporation specializing in early stage university business ventures, has partnered with Wayne State University to create GliaGen, which will specialize in novel diagnostic and therapeutic technologies specifically tailored to treat neurodegenerative diseases.
GliaGen has exclusively secured platform technology developed by Drs. Leon Carlock and Maria Cypher at the Center for Molecular Medicine and Genetics, Wayne State University School of Medicine.
“These technologies provide new tools for understanding neural disease processes, as well as cellular repair mechanisms,? Dr. Carlock said. ?This will significantly improve our ability to target these processes for diagnostic and therapeutic applications.?
In addition to commercializing the patent pending technology, GliaGen will also support further research at Wayne State.
?We expect our research support at the University in conjunction with the development efforts within GliaGen to enable the rapid translation of these very early stage discoveries into research, pharmaceutical and clinical applications,? said Chris Silva, CEO of Allied Minds.
“We also expect the success of this corporate model to provide future job opportunities for the WSU research staff, graduates and the Detroit community as a whole,? he said.
Eric Stief, WSU Technology Licensing Manager, said he sees the Allied Minds deal as an effective way to augment Dr. Carlock?s and Dr. Cypher?s groundbreaking research, and as a catalyst to speed basic science discoveries to commercial applications for the benefit of the public.
Allied Minds is a pre-seed investment company that creates partnerships with Universities to fund corporate spin-offs that result from successful early stage technology research.
